“Cellular Therapies, Longevity & You” with Special Guest GEORGE HAMILTON

DR. SAMUEL GOLPANIAN, a Leading Medical Expert, AND ACTOR GEORGE HAMILTON, Who has Undergone Experimental Treatment, Report from the Frontlines.

Monday, September 20, 5:30-7:00 p.m. EST

Stem cell therapy, one of the fastest growing medical trends, has been the subject of countless mainstream news reports  about how this promising health advancement has the potential to regenerate and repair damaged tissue, and possibly treat diseases and conditions for which few treatments currently exist. Due to the overwhelmingly  response we had at our last zoom presentation earlier this year, George Hamilton and Dr. Samuel Golpanian have agreed to an encore!

On Monday, September 20,  at 5:30 p.m.  Altima is proud to offer an exclusive opportunity to its subscribers to attend and participate in informational zoom presentation with actor George Hamilton, and  Dr. Samuel Golpanian, an expert on the state-of-the-science in stem cells therapy.  Dr. Golpanian will discuss how cellular therapies are being used to address age and orthopedic-related issues, and life-threatening conditions such as Aging Frailty, Alzheimer’s Disease, Metabolic Syndrome, Hypoplastic Left Heart Syndrome (HLHS), and Acute Respiratory Distress Syndrome (ARDS) associated with Covid-19 and influenza viruses.  George Hamilton will be sharing his personal experience.  Both will be available during the Q and A session following the 30 minute presentation.

This educational presentation will help enlighten participants in discerning fact from fiction, answer their questions about this exciting new science, and provide the latest data from LONGEVERON, a leading publicly-traded, Miami-based biotechnology company.  Attendance will be limited.

(Click on image below for better view)

During the forum, Dr. Golpanian will provide the latest data from LONGEVERON, NASDAQ (LGVN),  a leading local (Miami-based) biotechnology company.  He will separate fact from fiction, and answer questions from participants about this exciting new science, and help discern what is realistic and what is really being offered.

An industry leader and pioneer in this specialized field, LONGEVERON has been developing cellular therapies that specifically target age-related and life-threatening conditions, such as, Aging Frailty, Alzheimer’s disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).

Longeveron is conducting US FDA Phase I and II clinical trials for its investigational product, LOMECEL-B™, which is derived from medicinal signaling cells (MSCs) sourced from bone marrow of young, healthy adult donors.  In addition, Longeveron has received grants and funding from the National Institutes of Aging, the state of Maryland and the Alzheimer’s Association for its clinical trial programs.

With a mission to advance LOMOCEL-B, and other cell-based products/candidates into Phase 3 trials, the goal is to achieve regulatory approvals and broad use by the healthcare community. For more information visit

To learn more about this exciting and cutting edge experimental therapy, and to receive an exclusive invitation to the virtual forum,
please contact

Or call Jessica Protenic 305.781.5305